Excited to share our latest work led by Marta Ballester, Anita Kurilla, and colleagues, now accepted in Cell Reports. The amazing regulatory elements of Sox9 in regeneration and cancer! cell.com/cell-reports/fullte…
Huge kudos to the entire team—experimentalists, computational scientists, collaborators, and clinicians, who contributed their expertise, time, and energy. Huge thanks to BRIC, @cancer_dk and @UCPH_Research for support and scientific environment
Luis Arnes retweeted
We are excited to announce that today, @HRMrqz successfully defended her PhD thesis!
A new Doctor has emerged from our lab! 👏👏👏
Congrats Henar! 🥳🥳
Luis Arnes retweeted
We are excited to share our latest publication in @GenesDev! pubmed.ncbi.nlm.nih.gov/3979…
Luis Arnes retweeted
Did YOU fill out the survey on the shortage of PERT 🤔??
From the #EPC Public Affairs Committee!!
Help us analyze the current situation in Europe 🙏
1️⃣ QR-code for patients👇
1️⃣ QR-code for clinicians 👇 – at Lund, Sverige
I am excited to see this story by my talented Master's Student, Kristina Høj. Her research dives into age-related decline in pancreas regeneration and how it’s linked to a proinflammatory response to injury. @AGA_GHAdvances,@UCPH_BRIC, tinyurl.com/4e2uz2sb
Next steps: We’ll explore mechanisms behind the impaired regeneration, potentially leading to a new understanding of cancer risk factors and opportunities to prevent cancerous changes in the pancreas.
Many thanks to collaborators @JonathanBaldan, #PhilSeymour, @CVRift ,#JaneHasselby, @albin_san and all members of @ARNesLab for comments
Work supported by funding from @cancer_dk
@UCPH_BRIC
Luis Arnes retweeted
The Olive Lab is looking for a postdoc to lead our translational program on RAS inhibition in pancreatic cancer. Should have exceptional scientific and project management skills, and experience with transdisciplinary research. Must be a good human. olivelab.org
Kudos to Katarzyna Radke for winning a fellowship from the UEG! tinyurl.com/bdzctf3e @ARNeslab, @UCPH_BRIC, @UCPH_Research, @my_ueg
In collaboration with colleagues at Herlev Hospital and Rigshospitalet, Katarzyna will work towards precision therapy in pancreatic ductal adenocarcinoma and strategies to overcome therapy resistance using organoids.
ALT The image depicts pancreatic cancer organoids derived from ultrasound-guided fine-needle biopsies. GATA6 and MET are markers of molecular subtypes. Photo credit: Aida Marisch Delgado